{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T23:37:35Z","timestamp":1770248255653,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People who inject drugs (PWID) are at increased risk for viral hepatitis, yet hepatitis A virus (HAV) and hepatitis B virus (HBV) screening and immunization rates remain low. Although offering HAV and HBV services at syringe services programs (SSPs) is effective, few U.S. SSPs currently offer them. Limited qualitative research exists on the advantages and optimization of these services at SSPs. This study explored PWID and SSP staff perspectives regarding barriers to HAV and HBV prevention and care services in traditional healthcare, facilitators for SSP-based provision, and opportunities to improve service delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted at an SSP in Miami, Florida serving over 2500 PWID annually. Quantitative data on vaccine administration from August 2023 to May 2025 were abstracted from the SSP database. Prior to implementation, in May 2022, we conducted in-depth interviews with 15 PWID and 11 SSP staff. Transcripts were analyzed using codebook thematic analysis in Dedoose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From August 2023 to May 2025, the SSP administered 114 HAV and 176 HBV vaccine doses. Qualitative interviews from May 2022 revealed several key findings. Barriers included limited knowledge, stigma and discrimination, resource and transportation challenges, navigation difficulties, and limited prioritization. Facilitators for SSP-based services included the benefits of co-located, on-demand care, and non-stigmatizing and supportive environment. Opportunities for improvement included offering incentives, expanding outreach, and increasing communication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PWID face significant barriers to HAV and HBV services in traditional healthcare, including stigma, logistical challenges, and limited awareness of viral hepatitis. Integrating these services into SSPs enhanced accessibility and uptake by leveraging trust, convenience, and harm reduction principles.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-025-01391-w","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:38:13Z","timestamp":1767703093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on hepatitis A and B screening and immunization at a syringe services program: a mixed-methods study"],"prefix":"10.1186","volume":"23","author":[{"given":"Subul","family":"Malik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Plesons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Faraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler S.","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansel E.","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Edward","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"1391_CR1","unstructured":"Global Viral Hepatitis. Centers for disease control and prevention; June 6, 2024 Available from: https:\/\/www.cdc.gov\/hepatitis\/global\/index.html"},{"key":"1391_CR2","unstructured":"Viral Hepatitis Surveillance Report \u2013 United States. 2022: Centers for disease control and prevention; [updated April 2024. Available from: https:\/\/www.cdc.gov\/hepatitis-surveillance-2022\/about\/index.html"},{"key":"1391_CR3","unstructured":"Lopez K. Acute Hepatitis B in Miami-Dade County, 2012\u20132022. January 2023."},{"key":"1391_CR4","unstructured":"Hepatitis A Surveillance. December 2023 surveillance reports: https:\/\/www.floridahealth.gov\/diseases-and-conditions\/vaccine-preventable-disease\/hepatitis-a\/surveillance.html"},{"issue":"6","key":"1391_CR5","first-page":"1","volume":"63","author":"D Broz","year":"2014","unstructured":"Broz D, Wejnert C, Pham HT, DiNenno E, Heffelfinger JD, Cribbin M, et al. HIV infection and risk, prevention, and testing behaviors among injecting drug users\u2014National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ. 2014;63(6):1\u201351.","journal-title":"MMWR Surveill Summ"},{"issue":"6","key":"1391_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/0033354919874088","volume":"134","author":"R Koepke","year":"2019","unstructured":"Koepke R, Sill DN, Akhtar WZ, Mitchell KP, Guilfoyle SM, Westergaard RP, et al. Hepatitis A and hepatitis B vaccination coverage among persons who inject drugs and have evidence of hepatitis C infection. Public Health Rep. 2019;134(6):651\u20139.","journal-title":"Public Health Rep"},{"issue":"4","key":"1391_CR7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3390\/ijerph18041447","volume":"18","author":"PM Frew","year":"2021","unstructured":"Frew PM, Schamel JT, Randall LA, King AR, Holloway IW, Burris K, et al. Identifying missed opportunities for routine vaccination among people who use drugs. Int J Environ Res Public Health. 2021;18(4):1447.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1391_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11606-020-06201-6","volume":"36","author":"D Motavalli","year":"2021","unstructured":"Motavalli D, Taylor JL, Childs E, Valente PK, Salhaney P, Olson J, et al. Health is on the back burner: multilevel barriers and facilitators to primary care among people who inject drugs. J Gen Intern Med. 2021;36(1):129\u201337.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"1391_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1080\/10826084.2019.1710207","volume":"55","author":"L Miller-Lloyd","year":"2020","unstructured":"Miller-Lloyd L, Landry J, Macmadu A, Allard I, Waxman M. Barriers to healthcare for people who inject drugs: a survey at a syringe exchange program. Subst Use Misuse. 2020;55(6):896\u20139.","journal-title":"Subst Use Misuse"},{"key":"1391_CR10","doi-asserted-by":"publisher","first-page":"103112","DOI":"10.1016\/j.drugpo.2021.103112","volume":"93","author":"BE Meyerson","year":"2021","unstructured":"Meyerson BE, Russell DM, Kichler M, Atkin T, Fox G, Coles HB. I don\u2019t even want to go to the Doctor when I get sick now: healthcare experiences and discrimination reported by people who use drugs, Arizona 2019. Int J Drug Policy. 2021;93:103112.","journal-title":"Int J Drug Policy"},{"key":"1391_CR11","unstructured":"WHO publishes new guidelines on HIV, hepatitis and STIs for key populations. World Health Organization; [updated July 29, 2022. Available from: https:\/\/www.who.int\/news\/item\/29-07-2022-who-publishes-new-guidelines-on-hiv--hepatitis-and-sti-for-key-populations"},{"key":"1391_CR12","doi-asserted-by":"publisher","first-page":"104382","DOI":"10.1016\/j.drugpo.2024.104382","volume":"127","author":"O Price","year":"2024","unstructured":"Price O, Swanton R, Grebely J, Hajarizadeh B, Webb P, Peacock A, et al. Vaccination coverage among people who inject drugs: A systematic review. Int J Drug Policy. 2024;127:104382.","journal-title":"Int J Drug Policy"},{"issue":"Suppl 1Suppl 1","key":"1391_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/00333549141291S105","volume":"129","author":"CK Burr","year":"2014","unstructured":"Burr CK, Storm DS, Hoyt MJ, Dutton L, Berezny L, Allread V, et al. Integrating health and prevention services in syringe access programs: a strategy to address unmet needs in a high-risk population. Public Health Rep. 2014;129(Suppl 1Suppl 1):26\u201332.","journal-title":"Public Health Rep"},{"issue":"1","key":"1391_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.amepre.2008.03.028","volume":"35","author":"Y Hu","year":"2008","unstructured":"Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, et al. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med. 2008;35(1):25\u201332.","journal-title":"Am J Prev Med"},{"issue":"12","key":"1391_CR15","doi-asserted-by":"publisher","first-page":"ofz521","DOI":"10.1093\/ofid\/ofz521","volume":"6","author":"S Tressler","year":"2019","unstructured":"Tressler S, Bhandari R. Interventions to increase completion of hepatitis B vaccination in people who inject drugs: A systematic review and Meta-analysis. Open Forum Infect Dis. 2019;6(12):ofz521.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"1391_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/jvh.13759","volume":"29","author":"EW Hall","year":"2022","unstructured":"Hall EW, Gounder P, Angles J, Nelson NP, Rosenberg ES, Weng MK. Evaluating the cost-effectiveness of hepatitis B vaccination strategies in high-impact settings for adults. J Viral Hepat. 2022;29(12):1115\u201326.","journal-title":"J Viral Hepat"},{"issue":"11","key":"1391_CR17","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2105\/AJPH.91.11.1791","volume":"91","author":"DC Des Jarlais","year":"2001","unstructured":"Des Jarlais DC, Fisher DG, Newman JC, Trubatch BN, Yancovitz M, Paone D, et al. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am J Public Health. 2001;91(11):1791\u20132.","journal-title":"Am J Public Health"},{"issue":"1","key":"1391_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/jurban\/jti016","volume":"82","author":"FL Altice","year":"2005","unstructured":"Altice FL, Bruce RD, Walton MR, Buitrago MI. Adherence to hepatitis B virus vaccination at syringe exchange sites. J Urban Health. 2005;82(1):151\u201361.","journal-title":"J Urban Health"},{"issue":"4","key":"1391_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ypmed.2013.04.013","volume":"57","author":"L Topp","year":"2013","unstructured":"Topp L, Day CA, Wand H, Deacon RM, van Beek I, Haber PS, et al. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Prev Med. 2013;57(4):297\u2013303.","journal-title":"Prev Med"},{"key":"1391_CR20","volume-title":"Guidance on prevention of viral hepatitis B and C among people who inject drugs","author":"WHO","year":"2012","unstructured":"WHO. Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: World Health Organization; 2012."},{"key":"1391_CR21","unstructured":"Viral Hepatitis Among People Who Use or Inject Drugs. Centers for Disease Control and Prevention; [updated May 14, 2024. Available from: https:\/\/www.cdc.gov\/hepatitis\/hcp\/populations-settings\/pwid.html#:~:text=Key%20points,hepatitis%20B%20and%20hepatitis%20C"},{"issue":"RR\u20135","key":"1391_CR22","first-page":"1","volume":"61","author":"C Centers for Disease","year":"2012","unstructured":"Centers for Disease C, Prevention. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of health and human services. MMWR Recomm Rep. 2012;61(RR\u20135):1\u201340.","journal-title":"MMWR Recomm Rep"},{"key":"1391_CR23","doi-asserted-by":"publisher","first-page":"109540","DOI":"10.1016\/j.drugalcdep.2022.109540","volume":"237","author":"MP Montgomery","year":"2022","unstructured":"Montgomery MP, Zhong Y, Roberts E, Asher A, Bixler D, Doshani M, et al. Vaccination barriers and opportunities at syringe services programs in the united States, June-August 2021-A cross-sectional survey. Drug Alcohol Depend. 2022;237:109540.","journal-title":"Drug Alcohol Depend"},{"issue":"13","key":"1391_CR24","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1080\/10826084.2021.1958863","volume":"56","author":"NA Carnes","year":"2021","unstructured":"Carnes NA, Asher AK, Bohm MK, Bessler PA. Access to HIV, viral Hepatitis, and substance use disorder Treatment\/Overdose prevention services: A qualitative analysis of syringe service programs (SSPs) serving rural PWID. Subst Use Misuse. 2021;56(13):1933\u201340.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"1391_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.japh.2022.10.018","volume":"63","author":"TR Britton","year":"2023","unstructured":"Britton TR, Clague MR, Zagorski CM, Hill LG, Loera LJ. A wound care and immunization needs assessment for participants of a mobile syringe services program in Austin, TX. J Am Pharm Assoc (2003). 2023;63(1):361\u2013e.51.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"1391_CR26","unstructured":"APA handbook of research methods in psychology, Vol 2: research designs: quantitative, qualitative, neuropsychological, and biological. Cooper H, Camic PM, Long DL, Panter AT, Rindskopf D, Sher KJ, editors. Washington, DC: American Psychological Association; 2012. p. 701-x."},{"key":"1391_CR27","doi-asserted-by":"crossref","unstructured":"Poth C-A, Searle M. 30 essential skills for the qualitative researcher (2nd ed.) by John Creswell and Johanna Creswell B\u00e1ez. J Mixed Methods Res. 2021;15:155868982110281.","DOI":"10.1177\/15586898211028107"},{"issue":"Suppl 1","key":"1391_CR28","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/j.drugalcdep.2006.09.022","volume":"91","author":"JV Campbell","year":"2007","unstructured":"Campbell JV, Garfein RS, Thiede H, Hagan H, Ouellet LJ, Golub ET, et al. Convenience is the key to hepatitis A and B vaccination uptake among young adult injection drug users. Drug Alcohol Depend. 2007;91(Suppl 1):S64\u201372.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1391_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/ewjm.172.1.16","volume":"172","author":"KH Seal","year":"2000","unstructured":"Seal KH, Ochoa KC, Hahn JA, Tulsky JP, Edlin BR, Moss AR. Risk of hepatitis B infection among young injection drug users in San francisco: opportunities for intervention. West J Med. 2000;172(1):16\u201320.","journal-title":"West J Med"},{"issue":"4","key":"1391_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/jurban\/78.4.690","volume":"78","author":"AR Lifson","year":"2001","unstructured":"Lifson AR, Halcon LL. Substance abuse and high-risk needle-related behaviors among homeless youth in minneapolis: implications for prevention. J Urban Health. 2001;78(4):690\u20138.","journal-title":"J Urban Health"},{"issue":"2","key":"1391_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/oxfordjournals.epirev.a036161","volume":"16","author":"OS Levine","year":"1994","unstructured":"Levine OS, Vlahov D, Nelson KE. Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev. 1994;16(2):418\u201336.","journal-title":"Epidemiol Rev"},{"issue":"2","key":"1391_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/BF02287705","volume":"29","author":"DD Chitwood","year":"2002","unstructured":"Chitwood DD, Comerford M, McCoy HV. Satisfaction with access to health care among injection drug users, other drug users, and nonusers. J Behav Health Serv Res. 2002;29(2):189\u201397.","journal-title":"J Behav Health Serv Res"},{"issue":"6","key":"1391_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1377\/hlthaff.2024.00032","volume":"43","author":"O Heidari","year":"2024","unstructured":"Heidari O, Meyer D, Lowensen K, Patil A, O\u2019Conor KJ, LaRicci J, et al. Colocating syringe Services, COVID-19 Vaccination, and infectious disease testing: baltimore\u2019s experience. Health Aff (Millwood). 2024;43(6):883\u201391.","journal-title":"Health Aff (Millwood)"},{"key":"1391_CR34","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/1471-2458-14-820","volume":"14","author":"S Bowman","year":"2014","unstructured":"Bowman S, Grau LE, Singer M, Scott G, Heimer R. Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities. BMC Public Health. 2014;14:820.","journal-title":"BMC Public Health"},{"issue":"12 Suppl 2","key":"1391_CR35","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","volume":"224","author":"J Pattyn","year":"2021","unstructured":"Pattyn J, Hendrickx G, Vorsters A, Van Damme P, Hepatitis B, Vaccines. J Infect Dis. 2021;224(12 Suppl 2):S343\u201351.","journal-title":"J Infect Dis"},{"issue":"8","key":"1391_CR36","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jama.2018.1097","volume":"319","author":"A Two-Dose","year":"2018","unstructured":"Two-Dose A. Hepatitis B vaccine for adults (Heplisav-B). JAMA. 2018;319(8):822\u20133.","journal-title":"JAMA"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01391-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:37:23Z","timestamp":1770201443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-025-01391-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01391-w","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the University of Miami (IRB # 20240596) and was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all participants included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}